Drugs / PGE1
PGE1
English name Prostaglandin E1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT07604051 | Nov 2025 → Apr 2026 | — | Dr Mudassar Saeed Pansota | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT01467076 Comparator | Nov 2011 → May 2012 | newborn respiratory distress syndrome, pulmonary hypertension | NICHD Neonatal Research Network | Terminated | No outcome recorded |
| Phase 2/3 | NCT02223949 Comparator | Oct 2014 → Oct 2016 | obesity disorder | Hillel Yaffe Medical Center | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PGE1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01467076 ↗ |
| Known as | IPGE1 | “The objective of this study was to evaluate the feasibility of a randomized controlled trial (RCT) of inhaled PGE1 (IPGE1) in NHRF.” PMID 25496504 ↗ Dec 2014 |
| Known as | Prostaglandin E1 | “PGE1 (Prostaglandin E1) tablet is inserted in the posterior fornix” NCT02223949 ↗ |
| Route | Inhaled | “inhaled PGE1 (IPGE1)” PMID 25496504 ↗ Dec 2014 |